Format

Send to

Choose Destination
Expert Rev Proteomics. 2006 Jun;3(3):283-96.

Proteomics approaches to urologic diseases.

Author information

1
Molecular Urology Laboratory, Brigham & Women's Hospital, Harvard Medical School, 221 Longwood Avenue, LMRC-610, Boston, MA 02115, USA. bliu@partners.org

Abstract

Biomarkers are greatly needed for several urologic diseases, such as interstitial cystitis, the symptomatic and clinical progression of benign prostate hyperplasia, as well as the specific detection of urologic cancers, including prostate and bladder cancer. This review aims to: briefly describe the need for biomarkers in the field and biomarkers that are currently available for clinicians; address the limitations and roadblocks to effective biomarker discovery; and provide examples and strategies for implementing biomarkers in clinical practice and/or drug discovery.

PMID:
16771701
DOI:
10.1586/14789450.3.3.283
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center